Ready to play
Ready to play
A new study has shown that using continuous glucose monitoring devices, such as the Dexcom G7, benefits all type 2 diabetes patients, including those who do not require insulin. The study achieved a significant reduction in HbA1c levels from 8.8% to 7.2%, and an increase of about five additional hours per day with blood glucose within the target range (70-180 mg/dL). This was observed regardless of age, gender, ethnicity, income level, or the type of medication used. The researchers noted that approximately 97% of participants continued using the devices daily until the end of the study, further supporting the effectiveness of continuous glucose monitoring in diabetes management.
Notice: This Is an AI-Generated Summary
Comments (0)